



Risk Evaluation and Mitigation Strategy (REMS) Program Training

The educational module contains information on adverse reactions associated with YESCARTA and TECARTUS, including cytokine release syndrome and neurologic toxicities. These are not all of the adverse reactions associated with YESCARTA and TECARTUS.

Indication — YESCARTA®

YESCARTA® is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

Limitation of Use: YESCARTA® is not indicated for the treatment of patients with primary central nervous system lymphoma.

Please see full Prescribing Information, including **BOXED WARNING** and Medication Guide.

Indication — **TECARTUS™**

TECARTUS™ is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

This indication is approved under accelerated approval based on overall response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Please see full Prescribing Information, including **BOXED WARNING** and Medication Guide.

YESCARTA and TECARTUS REMS Program Overview



What is the YESCARTA and TECARTUS REMS (Risk Evaluation and Mitigation Strategy) Program?

A REMS Program is a strategy to manage known or potential risks associated with a drug and is required by the United States (US) Food and Drug Administration (FDA) to ensure that the benefits of the drug outweigh its risks. YESCARTA and TECARTUS are available only under a program called the YESCARTA and TECARTUS REMS Program because of the serious risks of cytokine release syndrome (CRS) and neurologic toxicities.

The goals of the YESCARTA and TECARTUS REMS Program are to mitigate the risks of CRS and neurologic toxicities by:

- Ensuring that hospitals and their associated clinics that dispense YESCARTA and/or TECARTUS are specially certified and have on-site, immediate access to a minimum of 2 doses of tocilizumab
- Ensuring that those relevant individuals who prescribe, dispense, or administer YESCARTA and/or TECARTUS are aware of how to manage the risks of CRS and neurologic toxicities

Hospital Certification

To become certified to dispense YESCARTA and/or TECARTUS, hospitals and their associated clinics must:

1. Designate an authorized representative to complete the training program by completing and submitting the YESCARTA and TECARTUS REMS Program Hospital Enrollment Form on behalf of the hospital and its associated clinics
2. Ensure that the authorized representative oversees implementation and compliance with the YESCARTA and TECARTUS REMS Program requirements
3. Dispense YESCARTA and/or TECARTUS only after verifying that a minimum of 2 doses of tocilizumab are available on-site for each patient and ready for administration within 2 hours
4. Recertify in the YESCARTA and TECARTUS REMS Program if a new authorized representative is designated

(continued on next page)

Hospital Certification (continued)

5. Maintain documentation that all processes and procedures are in place and are being followed for the YESCARTA and TECARTUS REMS Program; provide this documentation upon request to Kite, or a third party acting on behalf of Kite or FDA
6. Comply with audits by Kite, or a third party acting on behalf of Kite or FDA, to ensure that all training, processes, and procedures are in place and are being followed for the YESCARTA and TECARTUS REMS Program
7. Report any serious adverse events* suggestive of CRS or neurologic toxicities

*Serious adverse events are defined as any adverse experience occurring at any dose that results in any of the following outcomes: death, a life-threatening adverse experience, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect.

Who Can Be an Authorized Representative?

An authorized representative at the hospital and its associated clinics can be a:

- Physician
- Nurse
- Any responsible individual assigned by the hospital and its associated clinics

One representative (the “authorized representative”) must enroll for each hospital and its associated clinics and attest to the enrollment requirements as stated on the YESCARTA and TECARTUS REMS Program Hospital Enrollment Form.

YESCARTA and TECARTUS REMS Authorized Representative Attestations

- Complete the YESCARTA and TECARTUS REMS Program Training and successfully complete the YESCARTA and TECARTUS REMS Program Knowledge Assessment
- Submit the completed YESCARTA and TECARTUS REMS Program Hospital Enrollment Form to Kite via fax at 1-310-496-0397 or email to YTREMS@kitepharma.com
- Submit the YESCARTA and TECARTUS REMS Program Knowledge Assessment to Kite via fax at 1-310-496-0397 or email to YTREMS@kitepharma.com
- Oversee implementation and compliance with the YESCARTA and TECARTUS REMS Program

(continued on next page)

YESCARTA and TECARTUS REMS Authorized Representative Attestations (continued)

- Ensure that the hospital and its associated clinics will establish processes and procedures that are subject to monitoring by Kite or a third party acting on behalf of Kite to help ensure compliance with the requirements of the YESCARTA and TECARTUS REMS Program, including the following, before administering YESCARTA and/or TECARTUS:
 - Ensure that all relevant staff involved in the prescribing, dispensing, or administering of YESCARTA and/or TECARTUS are trained on the REMS Program requirements as described in the training materials, successfully complete the YESCARTA and TECARTUS REMS Program Knowledge Assessment, and maintain training records for all staff
 - The Authorized Representative will determine relevant staff who require training
 - Put processes and procedures in place to ensure that staff involved in the prescribing, dispensing, or administering of YESCARTA and/or TECARTUS are retrained if YESCARTA or TECARTUS has not been dispensed at least once annually from the date of certification in the YESCARTA and TECARTUS REMS Program
 - Prior to dispensing YESCARTA and/or TECARTUS, put processes and procedures in place to verify a minimum of 2 doses of tocilizumab are available on-site for each patient and are ready for immediate administration (within 2 hours)
 - Prior to patient discharge, provide patients/caregivers with the Patient Wallet Card

Serious Risks of YESCARTA and TECARTUS



Serious Risks Associated With YESCARTA

BOXED WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITIES

- Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving YESCARTA. Do not administer YESCARTA to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids
- Neurologic toxicities, including fatal or life-threatening reactions, occurred in patients receiving YESCARTA, including concurrently with CRS or after CRS resolution. Monitor for neurologic toxicities after treatment with YESCARTA. Provide supportive care and/or corticosteroids as needed

Serious Risks Associated With **TECARTUS**

BOXED WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITIES

- Cytokine Release Syndrome (CRS), including life-threatening reactions, occurred in patients receiving TECARTUS. Do not administer TECARTUS to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids
- Neurologic toxicities, including life-threatening reactions, occurred in patients receiving TECARTUS, including concurrently with CRS or after CRS resolution. Monitor for neurologic toxicities after treatment with TECARTUS. Provide supportive care and/or corticosteroids, as needed

Management of CRS

Cytokine Release Syndrome — YESCARTA

- CRS, including fatal or life-threatening reactions, occurred following treatment with YESCARTA
- In a Kite clinical trial, CRS occurred in 94% (101/108) of patients receiving YESCARTA, including Grade 3 or higher CRS in 13% (14/108) of patients
- The median time to onset was 2 days (range, 1-12 days)
- The median duration of CRS was 7 days (range, 2-58 days)
- 45% (49/108) of patients received tocilizumab after infusion of YESCARTA
- Among patients who died after receiving YESCARTA, 4 had ongoing CRS events at the time of death

Cytokine Release Syndrome — TECARTUS

- CRS, including life-threatening reactions, occurred following treatment with TECARTUS
- In a Kite clinical trial, CRS occurred in 91% (75/82) of patients receiving TECARTUS, including Grade 3 or higher CRS in 18% of patients
- Among the patients who died after receiving TECARTUS, one had a fatal CRS event
- The median time to onset was 3 days (range, 1-13 days)
- The median duration of CRS was 10 days (range, 1-50 days)

Patient Assessment of CRS Associated with YESCARTA

The following are signs and symptoms of CRS with YESCARTA	
Capillary leak syndrome	Hemophagocytic lymphohistiocytosis/ macrophage activation syndrome (HLH/MAS)
Cardiac arrest	Hypotension
Cardiac arrhythmias	Hypoxia
Cardiac failure	Renal insufficiency
Chills	Tachycardia
Fever	

Patient Assessment of CRS Associated with **TECARTUS**

The following are signs and symptoms of CRS with TECARTUS	
Alanine aminotransferase increased	Fever
Aspartate aminotransferase increased	Headache
Acute kidney injury	Hypotension
Chills	Hypoxia
Diarrhea	Nausea
Fatigue	Tachycardia

Guidance on Managing CRS for YESCARTA

- Identify CRS based on clinical presentation
- Evaluate for and treat other causes of fever, hypoxia, and hypotension
- If CRS is suspected, manage according to the recommendations on slide 21
- Tocilizumab, an interleukin-6 receptor antagonist, is recommended for the management of Grade 2 or higher CRS associated with YESCARTA
- Patients who experience Grade 2 or higher CRS (eg, hypotension, not responsive to fluids, or hypoxia requiring supplemental oxygenation) should be monitored with continuous cardiac telemetry and pulse oximetry
- For patients experiencing severe CRS, consider performing an echocardiogram to assess cardiac function
- For severe or life-threatening CRS, consider intensive care supportive therapy
- Monitor patients at least daily for 7 days at the certified hospitals and their associated clinics following infusion for signs and symptoms of CRS
- Monitor patients for signs or symptoms of CRS for 4 weeks after infusion

Guidance on Management of CRS for YESCARTA

Grading and Management of YESCARTA-Related CRS

CRS Grade*	Tocilizumab	Corticosteroids
Grade 1 Symptoms require symptomatic treatment only (eg, fever, nausea, fatigue, headache, myalgia, malaise)	N/A	N/A
Grade 2 Symptoms require and respond to moderate intervention Oxygen requirement less than 40% FiO ₂ or hypotension responsive to fluids or low dose of one vasopressor or Grade 2 organ toxicity†	Administer tocilizumab‡ 8 mg/kg intravenous over 1 hour (not to exceed 800 mg) If no clinical improvement in the signs and symptoms of CRS after the first dose, repeat tocilizumab every 8 hours as needed. Limit to a maximum of 3 doses in a 24-hour period; maximum total of 4 doses	Manage per Grade 3 if no improvement within 24 hours after starting tocilizumab
Grade 3 Symptoms require and respond to aggressive intervention Oxygen requirement greater than or equal to 40% FiO ₂ or hypotension requiring high-dose or multiple vasopressors or Grade 3 organ toxicity or Grade 4 transaminitis	Per Grade 2	Administer methylprednisolone 1 mg/kg intravenous twice daily or equivalent dexamethasone (eg, 10 mg intravenous every 6 hours) Continue corticosteroids use until the event is Grade 1 or less, then taper over 3 days
Grade 4 Life-threatening symptoms Requirements for ventilator support, CVVHD, or Grade 4 organ toxicity (excluding transaminitis)	Per Grade 2	Administer methylprednisolone 1000 mg intravenous per day for 3 days; if improves, then manage as above

Abbreviation: CVVHD, continuous veno-venous hemodialysis.

*Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. *Blood*. 2014;124(2):188-195.

†Refer to the table on slide 30 for management of neurologic toxicity.

‡Refer to tocilizumab Prescribing Information for details.

Guidance on Managing CRS for **TECARTUS**

- Identify CRS based on clinical presentation
- Evaluate for and treat other causes of fever, hypoxia, and hypotension
- If CRS is suspected, manage according to the recommendations on slide 23
- Tocilizumab, an interleukin-6 receptor antagonist, is recommended for the management of Grade 1 or higher CRS associated with TECARTUS
- Patients who experience Grade 2 or higher CRS (eg, hypotension, not responsive to fluids, or hypoxia requiring supplemental oxygenation) should be monitored with continuous cardiac telemetry and pulse oximetry
- For patients experiencing severe CRS, consider performing an echocardiogram to assess cardiac function
- For severe or life-threatening CRS, consider intensive care supportive therapy
- Monitor patients at least daily for 7 days at the certified hospitals and their associated clinics following infusion for signs and symptoms of CRS
- Monitor patients for signs or symptoms of CRS for 4 weeks after infusion

Guidance on Management of CRS for TECARTUS

Grading and Management of TECARTUS-Related CRS

CRS Grade*	Tocilizumab	Corticosteroids
Grade 1 Symptoms require symptomatic treatment only (eg, fever, nausea, fatigue, headache, myalgia, malaise)	If not improving after 24 hours, administer tocilizumab 8 mg/kg IV over 1 hour (not to exceed 800 mg)	N/A
Grade 2 Symptoms require and respond to moderate intervention Oxygen requirement less than 40% FiO ₂ or hypotension responsive to fluids or low dose of one vasopressor or Grade 2 organ toxicity†	Administer tocilizumab‡ 8 mg/kg intravenously over 1 hour (not to exceed 800 mg) Repeat tocilizumab every 8 hours as needed if not responsive to intravenous fluids or increasing supplemental oxygen. Limit to a maximum of 3 doses in a 24-hour period; maximum total of 4 doses if no clinical improvement in the signs and symptoms of CRS If improving, discontinue tocilizumab	Manage per Grade 3 if no improvement within 24 hours after starting tocilizumab If improving, taper corticosteroids, and manage as Grade 1
Grade 3 Symptoms require and respond to aggressive intervention Oxygen requirement greater than or equal to 40% FiO ₂ or hypotension requiring high-dose or multiple vasopressors or Grade 3 organ toxicity or Grade 4 transaminitis	Per Grade 2 If improving, discontinue tocilizumab	Administer methylprednisolone 1 mg/kg intravenously twice daily or equivalent dexamethasone (eg, 10 mg intravenously every 6 hours) until Grade 1, then taper corticosteroids If improving, manage as Grade 2 If not improving, manage as Grade 4
Grade 4 Life-threatening symptoms Requirements for ventilator support, CVVHD, or Grade 4 organ toxicity (excluding transaminitis)	Per Grade 2 If improving, discontinue tocilizumab	Administer methylprednisolone 1000 mg intravenously per day for 3 days If improving, taper corticosteroids, and manage as Grade 3 If not improving, consider alternate immunosuppressants

Abbreviation: CVVHD, continuous veno-venous hemodialysis.

*Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. *Blood*. 2014;124(2):188-195.

†Refer to the table on slide 32 for management of neurologic toxicity.

‡Refer to tocilizumab Prescribing Information for details.

Management of Neurologic Toxicities

Neurologic Toxicities — YESCARTA

- Neurologic toxicities, that were fatal or life-threatening, occurred following treatment with YESCARTA
- Neurologic toxicities occurred in 87% of patients, including Grade 3 or higher neurologic toxicities in 31% of patients
- 98% of all neurologic toxicities occurred within the first 8 weeks of YESCARTA infusion
- The median time to onset was 4 days (range, 1-43 days) following YESCARTA infusion
- The median duration was 17 days
- Prolonged encephalopathy lasting up to 173 days was noted
- Serious events including leukoencephalopathy and seizures occurred with YESCARTA
- Fatal and serious cases of cerebral edema have occurred in patients treated with YESCARTA

Neurologic Toxicities — TECARTUS

- Neurologic events, including those that were life-threatening, occurred following treatment with TECARTUS
- Neurologic events occurred in 81% of patients, 37% of whom experienced Grade 3 or higher (severe or life threatening) adverse reactions
- 85% of all treated patients experienced the first CRS or neurological event within the first 7 days after TECARTUS infusion
- The median time to onset was 6 days (range, 1-32 days) following TECARTUS infusion
- The median duration was 21 days (range, 2-454 days)
- Serious events including encephalopathy, aphasia, and seizures occurred with TECARTUS

Patient Assessment of Neurologic Toxicities Associated With YESCARTA

The following are common signs and symptoms of neurologic toxicities	
Anxiety	Encephalopathy
Aphasia	Headache
Delirium	Insomnia
Dizziness	Tremor

Patient Assessment of Neurologic Toxicities Associated With TECARTUS

The following are common signs and symptoms of neurologic toxicities	
Aphasia	Headache
Delirium	Tremor
Encephalopathy	

Guidance on Managing Neurologic Toxicities for YESCARTA and TECARTUS

- Monitor patients for signs and symptoms of neurologic toxicities
- Rule out other causes of neurologic symptoms
- Patients who experience Grade 2 or higher neurologic toxicities should be monitored with continuous cardiac telemetry and pulse oximetry
- Provide intensive care supportive therapy for severe or life-threatening neurologic toxicities
- Consider nonsedating, antiseizure medicines (eg, levetiracetam) for seizure prophylaxis for any Grade 2 or higher neurologic toxicities
- Monitor patients at least daily for 7 days at the certified hospitals and their associated clinics following infusion for signs and symptoms of neurologic toxicities
- Monitor patients for signs or symptoms of neurologic toxicities for 4 weeks after infusion and treat promptly

Guidance on Managing Neurologic Toxicities for YESCARTA

Grading and Management of YESCARTA-Related Neurologic Toxicities

Neurologic Event (Grading Assessment CTCAE 4.03)*	Concurrent CRS	No Concurrent CRS
Grade 1 Examples include: Somnolence—mild drowsiness or sleepiness Confusion—mild disorientation Encephalopathy—mild limiting of ADLs Dysphasia—not impairing ability to communicate	Supportive care	Supportive care
Grade 2 Examples include: Somnolence—moderate, limiting instrumental ADLs Confusion—moderate disorientation Encephalopathy—limiting instrumental ADLs Dysphasia—moderate impairing ability to communicate spontaneously Seizure(s)	Administer tocilizumab per the table on slide 21 for management of Grade 2 CRS If no improvement within 24 hours after starting tocilizumab, administer dexamethasone 10 mg intravenous every 6 hours if not already taking other corticosteroids Continue dexamethasone use until the event is Grade 1 or less, then taper over 3 days Consider nonsedating, antiseizure medicines (eg, levetiracetam) for seizure prophylaxis	Administer dexamethasone 10 mg intravenous every 6 hours Continue dexamethasone use until the event is Grade 1 or less, then taper over 3 days Consider nonsedating, antiseizure medicines (eg, levetiracetam) for seizure prophylaxis

Abbreviation: ADL=activities of daily living.

*National Institutes of Health, National Cancer Institute. *Common Terminology Criteria for Adverse Events (CTCAE)*. Version 4.03. Bethesda, MD: National Institutes of Health; 2009. Revised June 2010. NIH publication 09-5410.

Guidance on Managing Neurologic Toxicities for YESCARTA

Grading and Management of YESCARTA-Related Neurologic Toxicities (continued)

Neurologic Event (Grading Assessment CTCAE 4.03)*	Concurrent CRS	No Concurrent CRS
<p>Grade 3 Examples include: Somnolence—obtundation or stupor Confusion—severe disorientation Encephalopathy—limiting self-care ADLs Dysphasia—severe receptive or expressive characteristics, impairing ability to read, write, or communicate intelligibly</p>	<p>Administer tocilizumab per the table on slide 21 for management of Grade 2 CRS In addition, administer dexamethasone 10 mg intravenous with the first dose of tocilizumab and repeat dose every 6 hours. Continue dexamethasone use until the event is Grade 1 or less, then taper over 3 days Consider non-sedating, antiseizure medicines (eg, levetiracetam) for seizure prophylaxis</p>	<p>Administer dexamethasone 10 mg intravenous every 6 hours Continue dexamethasone use until the event is Grade 1 or less, then taper over 3 days Consider non-sedating, antiseizure medicines (eg, levetiracetam) for seizure prophylaxis</p>
<p>Grade 4 Life-threatening consequences Urgent intervention indicated Requirement for mechanical ventilation Consider cerebral edema</p>	<p>Administer tocilizumab per the table on slide 21 for management of Grade 2 CRS Administer methylprednisolone 1000 mg intravenous per day with first dose of tocilizumab and continue methylprednisolone 1000 mg intravenous per day for 2 more days; if improves, then manage as above Consider non-sedating, antiseizure medicines (eg, levetiracetam) for seizure prophylaxis</p>	<p>Administer methylprednisolone 1000 mg intravenous per day for 3 days; if improves, then manage as above Consider non-sedating, antiseizure medicines (eg, levetiracetam) for seizure prophylaxis</p>

Abbreviation: ADL=activities of daily living.

*National Institutes of Health, National Cancer Institute. *Common Terminology Criteria for Adverse Events (CTCAE)*. Version 4.03. Bethesda, MD: National Institutes of Health; 2009. Revised June 2010. NIH publication 09-5410.

Guidance on Managing Neurologic Toxicities for **TECARTUS**

Grading and Management of TECARTUS-Related Neurologic Toxicities

Neurologic Event*	Concurrent CRS	No Concurrent CRS
Grade 1 Examples include: Somnolence—mild drowsiness or sleepiness Confusion—mild disorientation Encephalopathy—mild limiting of ADLs Dysphasia—not impairing ability to communicate	Administer tocilizumab per the table on slide 23 for management of Grade 1 CRS	Supportive care
Grade 2 Examples include: Somnolence—moderate, limiting instrumental ADLs Confusion—moderate disorientation Encephalopathy—limiting instrumental ADLs Dysphasia—moderate impairing ability to communicate spontaneously Seizure(s)	Administer tocilizumab per the table on slide 23 for management of Grade 2 CRS If not improving within 24 hours after starting tocilizumab, administer dexamethasone 10 mg intravenously every 6 hours until the event is Grade 1 or less, then taper corticosteroids If improving, discontinue tocilizumab If still not improving, manage as Grade 3	Administer dexamethasone 10 mg intravenously every 6 hours until the event is Grade 1 or less If improving, taper corticosteroids
	Consider non-sedating, antiseizure medicines (eg, levetiracetam) for seizure prophylaxis	

Abbreviation: ADL=activities of daily living.

*National Institutes of Health, National Cancer Institute. *Common Terminology Criteria for Adverse Events (CTCAE)*.

Guidance on Managing Neurologic Toxicities for **TECARTUS**

Grading and Management of TECARTUS-Related Neurologic Toxicities (continued)

Neurologic Event*	Concurrent CRS	No Concurrent CRS
Grade 3 Examples include: Somnolence—obtundation or stupor Confusion—severe disorientation Encephalopathy—limiting self-care ADLs Dysphasia—severe receptive or expressive characteristics, impairing ability to read, write, or communicate intelligibly	Administer tocilizumab per the table on slide 23 for management of Grade 2 CRS In addition, administer dexamethasone 10 mg intravenously with the first dose of tocilizumab and repeat dose every 6 hours. Continue dexamethasone use until the event is Grade 1 or less, then taper corticosteroids If improving, discontinue tocilizumab and manage as Grade 2 If still not improving, manage as Grade 4	Administer dexamethasone 10 mg intravenously every 6 hours Continue dexamethasone use until the event is Grade 1 or less, then taper corticosteroids If not improving, manage as Grade 4
	Consider non-sedating, antiseizure medicines (eg, levetiracetam) for seizure prophylaxis	
Grade 4 Life-threatening consequences Urgent intervention indicated Requirement for mechanical ventilation Consider cerebral edema	Administer tocilizumab per the table on slide 23 for management of Grade 2 CRS Administer methylprednisolone 1000 mg intravenously per day with first dose of tocilizumab and continue methylprednisolone 1000 mg intravenously per day for 2 more days If improving, then manage as Grade 3 If not improving, consider alternate immunosuppressants	Administer methylprednisolone 1000 mg intravenously per day for 3 days If improving, then manage as Grade 3 If not improving, consider alternate immunosuppressants
	Consider non-sedating, antiseizure medicines (eg, levetiracetam) for seizure prophylaxis	

Abbreviation: ADL=activities of daily living.

*National Institutes of Health, National Cancer Institute. *Common Terminology Criteria for Adverse Events (CTCAE)*.

Adverse Event Reporting

Adverse Event Reporting

Reporting suspected adverse events after administration of therapy is important. It allows continued monitoring of the risk/benefit balance of therapy.

Hospitals and its associated clinics must report any serious adverse event* suggestive of CRS or neurologic toxicities to Kite at **1-844-454-KITE** (5483) or medinfo@kitepharma.com or FDA at **1-800-FDA-1088** or www.fda.gov/medwatch.

Healthcare providers are also encouraged to report any suspected serious adverse events* associated with YESCARTA or TECARTUS as outlined above.

*Serious adverse events are defined as any adverse experience occurring at any dose that results in any of the following outcomes: death, a life-threatening adverse experience, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect

Patient Counseling



Patient Counseling

- Talk to the patient about the risk of CRS and neurologic toxicities. Tell them to contact their healthcare provider and/or seek immediate care if experiencing the signs and symptoms associated with CRS and neurologic toxicities:
 - Fever (100.4°F/38°C or higher)
 - Difficulty breathing
 - Chills or shaking chills
 - Confusion
 - Dizziness or lightheadedness
 - Severe nausea, vomiting, or diarrhea
 - Fast or irregular heartbeat
 - Severe fatigue or weakness
- Provide the YESCARTA and TECARTUS REMS Patient Wallet Card to the patient or the patient's caregiver. Tell the patient to carry the Patient Wallet Card at all times and to share the Patient Wallet Card with any healthcare provider involved in the patient's treatment
- Advise patients to refrain from driving or operating heavy or potentially dangerous machinery until at least 8 weeks after YESCARTA or TECARTUS infusion
- Instruct patient to remain within close proximity (within 2 hours) of the certified administering hospital and its associated clinics for at least 4 weeks following YESCARTA or TECARTUS infusion

YESCARTA and TECARTUS REMS Program Resources

YESCARTA and TECARTUS REMS Program Kit

Includes:

- YESCARTA full Prescribing Information and Medication Guide
- TECARTUS full Prescribing Information and Medication Guide
- YESCARTA and TECARTUS REMS Program Training
- YESCARTA and TECARTUS REMS Program Knowledge Assessment
- YESCARTA and TECARTUS REMS Program Hospital Enrollment Form
- YESCARTA and TECARTUS Adverse Reaction Management Guide
- YESCARTA and TECARTUS Patient Wallet Card

Additional YESCARTA and TECARTUS REMS Program Information and Resources

To enroll in the YESCARTA and TECARTUS REMS Program or obtain information regarding enrollment in the program, call 1-844-454-KITE or visit the YESCARTA and TECARTUS REMS Program website at www.YescartaTecartusREMS.com. The REMS Program website contains the most current version of REMS-related materials.

YESCARTA, the YESCARTA Logo, TECARTUS, the TECARTUS Logo, KITE, and the KITE Logo are trademarks of Kite Pharma, Inc. Gilead is a trademark of Gilead Sciences Inc.
©2020 Kite Pharma, Inc. All rights reserved. REMS-CTF-0002 07/2020